The Benefit of Acarbose in NIDDM Patients with Secondary Failure to Glibenclamide (Manfaat Akarbose pada Pengobatan Diabetes Melitus tidak Tergantung Insulin (DMTTI) Gagal Sekunder Sulfonilurea) | Perpustakaan Badan Kebijakan Pembangunan Kesehatan

Search by :

ALL Author Subject ISBN/ISSN Advanced Search

Last search:

Text

The Benefit of Acarbose in NIDDM Patients with Secondary Failure to Glibenclamide (Manfaat Akarbose pada Pengobatan Diabetes Melitus tidak Tergantung Insulin (DMTTI) Gagal Sekunder Sulfonilurea)

et al - Personal Name; Sampeliling, A. - Personal Name;

Arround 10 percent NIDDM patients will develope secondary failure every year. Acarbose could lower the absorbtion of glucose from the intestines. The aim of the study is to evaluate the benefit of acorbose as adjuvant treatment to NIDDM with secondary failure to glibenclamide. Patients were secondary failure to glibenclamide include to the study. The study was done in two phases. First phase: treatment with glibenclamide 15 mg/day for 12 weeks. Second phase: acarbose 2x 100 mg/day were added for the next 12 weeks. At week 0.12 and 14 fasting blood sugar, one hour and two hours post prandial, HbA and serum lipids were examined. Addition of acarbose in NIDDM patients with secondary failure to glibenclamide not only improved the glycemic control but also the fasting insulin level and serum lipid profiles.

Availability

Location name is not set Location name is not set

A00001190

Available

Detail Information

Series Title: -
Call Number: Majalah Kedokteran Indonesia,46(9)1996:484-488
Publisher: : ., 1996
Collation: -
Language
ISBN/ISSN: -
Classification: -
Content Type: -
Media Type: -
Carrier Type: -
Edition: -
Subject(s): diabetes mellitus, non-insulin-dependent
Specific Detail Info: -
Statement of Responsibility: -

Other version/related

No other version available

File Attachment

No Data

Comments

You must be logged in to post a comment